<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00435994</url>
  </required_header>
  <id_info>
    <org_study_id>0311-21</org_study_id>
    <nct_id>NCT00435994</nct_id>
  </id_info>
  <brief_title>Assessment of Airway Obstruction in Infants With Lower Respiratory Infections</brief_title>
  <official_title>Assessment of Airway Obstruction in Infants With Lower Respiratory Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how two different aerosol medications may improve
      airway function in infants with respiratory illness. We are using two different medications
      and comparing the difference in lung function after each medication. We will also be taking a
      nasal wash sample for VEGF. We will be using this in comparing how infants respond to the
      aerosol medications as well. We hope to help standardize medications used for infants with
      bronchiolitis and RSV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that VEGF production is higher in children with RSV infection than in children
      with other viral infections and normal controls. In addition, the degree of VEGF production
      is related to severity of airway obstruction. We also hypothesize that infants with higher
      VEGF levels are more likely to improve lung function following racemic epinephrine than
      albuterol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung Function</measure>
    <time_frame>Baseline, Post bronchodilator (up to 10 minutes, Post-epinephrine (up to 30 minutes)</time_frame>
    <description>Lung functions were obtained under sedation using Chloral Hydrate. Forced expiratory flows are a lung volume at which the airway pressure is equal to 30 cm H2O (V30). Forced expiratory flows are measured at 75% FVC (FEF75). Measurements were repeated post bronchodilator and again post Epinephrine. A higher Z-score reflects better lung function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Growth Factor (VEGF)</measure>
    <time_frame>During nasal wash</time_frame>
    <description>Analysis for VEGF level by ELISA</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Bronchiolitis</condition>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Infants with viral lower respiratory infections</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy infants between the ages of 2-24 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bronchiolitis-Nasal wash only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled primatene will be given as a breathing treatment</intervention_name>
    <description>While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.</description>
    <arm_group_label>Infants with viral lower respiratory infections</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
    <other_name>epinephrine 0.5ml of the 2.25% concentration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal Washing</intervention_name>
    <description>1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence</description>
    <arm_group_label>Infants with viral lower respiratory infections</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Bronchiolitis-Nasal wash only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1 Infants between 2 and 24 months that are healthy

          -  Group 2 Infants between 2 and 24 months that have RSV or bronchiolitis and defined as
             the first episode of wheezing

        Exclusion Criteria:

          -  Group 1 and 2 - no cardiac disease, no oxygen requirement, prematurity &lt; 37 weeks, and
             cannot be in the ICU.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S. Tepper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2007</study_first_posted>
  <results_first_submitted>November 12, 2015</results_first_submitted>
  <results_first_submitted_qc>May 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2016</results_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infant</keyword>
  <keyword>Respiratory Syncytial Virus</keyword>
  <keyword>Bronchiolitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Airway Obstruction</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Control</title>
          <description>Healthy infants between the ages of 2-24 month without a history of congenital heart disease or prematurity</description>
        </group>
        <group group_id="P2">
          <title>Respiratory Syncytial Virus</title>
          <description>Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by a URI</description>
        </group>
        <group group_id="P3">
          <title>Bronchiolitis-Nasal Wash Only</title>
          <description>Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15">7 of the subjects were consented and did not complete the study procedures.</participants>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Control</title>
          <description>Healthy infants between the ages of 2-24 month without a history of congenital heart disease or prematurity</description>
        </group>
        <group group_id="B2">
          <title>Respiratory Syncytial Virus</title>
          <description>Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by a URI</description>
        </group>
        <group group_id="B3">
          <title>Bronchiolitis</title>
          <description>Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13" spread="5"/>
                    <measurement group_id="B2" value="7" spread="6"/>
                    <measurement group_id="B3" value="7" spread="4"/>
                    <measurement group_id="B4" value="11" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lung Function</title>
        <description>Lung functions were obtained under sedation using Chloral Hydrate. Forced expiratory flows are a lung volume at which the airway pressure is equal to 30 cm H2O (V30). Forced expiratory flows are measured at 75% FVC (FEF75). Measurements were repeated post bronchodilator and again post Epinephrine. A higher Z-score reflects better lung function.</description>
        <time_frame>Baseline, Post bronchodilator (up to 10 minutes, Post-epinephrine (up to 30 minutes)</time_frame>
        <population>All participants who had baseline, post bronchodilator and post epinephrine measurements were included. Participants in the Bronchiolitis arm did not have infant pulmonary functions obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy infants between the ages of 2-24 month without a history of congenital heart disease or prematurity had spirometry performed under sedation.</description>
          </group>
          <group group_id="O2">
            <title>Respiratory Syncytial Virus</title>
            <description>Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by a URI</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function</title>
          <description>Lung functions were obtained under sedation using Chloral Hydrate. Forced expiratory flows are a lung volume at which the airway pressure is equal to 30 cm H2O (V30). Forced expiratory flows are measured at 75% FVC (FEF75). Measurements were repeated post bronchodilator and again post Epinephrine. A higher Z-score reflects better lung function.</description>
          <population>All participants who had baseline, post bronchodilator and post epinephrine measurements were included. Participants in the Bronchiolitis arm did not have infant pulmonary functions obtained.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.071" spread="0.586"/>
                    <measurement group_id="O2" value="-3.179" spread="2.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Bronchodilator</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.186" spread="0.639"/>
                    <measurement group_id="O2" value="-3.345" spread="2.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Epinephrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.041" spread="0.802"/>
                    <measurement group_id="O2" value="-2.430" spread="2.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Growth Factor (VEGF)</title>
        <description>Analysis for VEGF level by ELISA</description>
        <time_frame>During nasal wash</time_frame>
        <population>Due to limited samples and the length of time that has passed since they were obtained, we are unable to separate Bronchiolitis from RSV.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy infants between the ages of 2-24 month without a history of congenital heart disease or prematurity</description>
          </group>
          <group group_id="O2">
            <title>Bronchiolitis and Respiratory Syncytial Virus-Nasal Wash Only</title>
            <description>Infants 2 months to 24 months who were diagnosed with bronchiolitis and respiratory syncytial virus received nasal wash only.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Growth Factor (VEGF)</title>
          <description>Analysis for VEGF level by ELISA</description>
          <population>Due to limited samples and the length of time that has passed since they were obtained, we are unable to separate Bronchiolitis from RSV.</population>
          <units>pg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.526" spread="223.268"/>
                    <measurement group_id="O2" value="568.867" spread="407.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0020</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Healthy Control</title>
        </group>
        <group group_id="E2">
          <title>Respiratory Syncytial Virus</title>
        </group>
        <group group_id="E3">
          <title>Bronchiolitis</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>More than half of our infants woke up before completion of the protocol therefore limiting our analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Tepper, MD, Ph.D.</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-274-9647</phone>
      <email>rtepper@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

